

CORRESPONDENCE

Open Access



# Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group

The MENA Pompe Working Group, Fatma Al Jasmi<sup>1</sup>, Mohammed Al Jumah<sup>2,3</sup>, Fatimah Alqarni<sup>4</sup>, Nouriya Al-Sanna'a<sup>5</sup>, Fawziah Al-Sharif<sup>6</sup>, Saeed Bohlega<sup>7</sup>, Edward J. Cupler<sup>8\*</sup>, Waseem Fathalla<sup>9</sup>, Mohamed A. Hamdan<sup>10</sup>, Nawal Makhseed<sup>11</sup>, Shahriar Nafissi<sup>12</sup>, Yalda Nilipour<sup>13</sup>, Laila Selim<sup>14</sup>, Nuri Shembesh<sup>15</sup>, Rawda Sunbul<sup>16</sup> and Seyyed Hassan Tonekaboni<sup>17</sup>

## Abstract

**Background:** Pompe disease is a rare autosomal recessive disorder caused by a deficiency of the lysosomal enzyme alpha-glucosidase responsible for degrading glycogen. Late-onset Pompe disease has a complex multisystem phenotype characterized by a range of symptoms.

**Methods:** An expert panel from the Middle East and North Africa (MENA) region met to create consensus-based guidelines for the diagnosis and treatment of late-onset Pompe disease for the MENA region, where the relative prevalence of Pompe disease is thought to be high but there is a lack of awareness and diagnostic facilities.

**Results:** These guidelines set out practical recommendations and include algorithms for the diagnosis and treatment of late-onset Pompe disease. They detail the ideal diagnostic workup, indicate the patients in whom enzyme replacement therapy should be initiated, and provide guidance on appropriate patient monitoring.

**Conclusions:** These guidelines will serve to increase awareness of the condition, optimize patient diagnosis and treatment, reduce disease burden, and improve patient outcomes.

## Introduction

Pompe disease, also known as acid maltase deficiency (AMD) or glycogen storage disease type II (GSDII), is a rare autosomal recessive disorder of glycogen metabolism caused by insufficient activity of the enzyme acid alpha-glucosidase (GAA). There are two forms of the disease: infantile-onset Pompe disease (IOPD; aged <1 year with cardiomyopathy) and late-onset Pompe disease (LOPD; >1 year of age through to adulthood or <1 year without cardiomyopathy). The worldwide incidence of both forms of the disease is commonly reported to be 1 in 40,000 [1], however prospective trials suggest the incidence may be as high as approximately 1 in 9,000 [2, 3].

Myozyme<sup>®</sup> (alglucosidase alfa) was approved for the treatment of Pompe disease in Europe and the United States in 2006 and has changed the management of Pompe disease, improving the symptoms of the disease in many, but not all, patients [4]. Additionally, enzyme replacement therapy (ERT) with alglucosidase alfa extends life expectancy in patients with LOPD [5].

A number of guidelines exist for the diagnosis and treatment of LOPD [6–8]; however these do not address the challenges faced by the Middle East and North Africa (MENA) region in the diagnosis and treatment of LOPD, namely delayed diagnosis, access to diagnostic tools, and access to treatment. There is, therefore, a need for region-specific recommendations for the diagnosis and treatment of LOPD which assess the latest available literature and tailor it to the region with due consideration of local experiences and challenges. The objective of this paper is to

\* Correspondence: cuplere@gmail.com

<sup>8</sup>Department of Neuroscience, MBC J-76, King Faisal Specialist Hospital and Research Center, P.O. Box 40047, Jeddah 21499, Kingdom of Saudi Arabia  
Full list of author information is available at the end of the article

provide clinical guidelines on the diagnosis and treatment of LOPD in the MENA region.

## Methods

A panel of experts met to develop consensus recommendations to aid diagnosis and treatment of infantile- and late-onset Pompe disease in the MENA region. The panel of physicians from across the MENA region included experts from different specialties – adult and pediatric neurology, metabolic diseases, genetics, pediatric cardiology, and neuropathology – all with expertise in the diagnosis and/or management of Pompe disease.

A literature review was performed prior to the meeting. A search for relevant articles including randomized control trials, review articles, and most recent international guidelines on the diagnosis and treatment of LOPD was undertaken using PubMed. The search terms included: *late onset Pompe disease, glycogen storage disease type II, lysosomal storage disorders, acid alpha-glucosidase deficiency, and acid maltase deficiency.*

The panel critically analyzed and discussed these articles at the meeting. The validity, clinical relevance, and applicability of the evidence for LOPD in the MENA region were discussed. After considering the evidence, the panel achieved a consensus on a number of recommendations that are supported by best scientific evidence.

## Background

Pompe disease was first characterized in 1932 by Joannes C. Pompe, who described glycogen accumulation in cardiac muscle in a 7-month-old girl who died [9]. Pompe disease was first categorized as GSDII by G.T. Cori in 1954 [10], and further understanding of the disease was achieved with the discovery of lysosomes in 1955 by Christian de Duve [11, 12]. In 1963, Henri Hers identified GAA as the enzyme that is deficient in Pompe patients and therefore responsible for Pompe disease [13].

Following the discovery of GAA deficiency as the cause of Pompe disease, a number of enzyme replacement trials have been conducted. In 1964, Baudhuin and colleagues intramuscularly injected an extract of the fungus *Aspergillus niger*, which was shown to contain GAA, into a patient with abnormal lysosomes; however the treatment did not demonstrate any appreciable change in the lysosomes [14].

In 1974, ERT using enzymes purified from a human source were administered to two patients with Gaucher's disease [15]. Exogenous glucocerebrosidase was found to cause a definite decrease in the quantity of accumulated lipids, but the results were largely disappointing. The first successful ERT of a lysosomal storage disorder in humans was achieved in 1991 when Barton and colleagues reported the results of infusion of macrophage-targeted human placental glucocerebrosidase into 12 patients with

type 1 Gaucher's disease [16]. In the same year, the first successful *in vivo* study of GAA ERT was reported [17]. Van der Ploeg and colleagues reported that a human placenta-derived GAA delivered by a mannose 6-phosphate receptor-mediated ERT had resulted in cardiac uptake in mice, offering the potential for a treatment for Pompe disease.

This potential was realized in 2001 when the first clinical studies of ERT infusion in IOPD patients were published [18, 19]. These showed that recombinant human GAA (rhGAA) derived from either Chinese hamster ovary (CHO) cells or transgenic rabbit milk is capable of improving cardiac and skeletal muscle function. Longer term studies confirmed the tolerability, safety, and efficacy of ERT in Pompe disease [20, 21], resulting in the regulatory approvals of alglucosidase alfa for the treatment of Pompe disease in 2006 [22].

The first randomized controlled study of ERT in LOPD patients was published in 2010 [23] and demonstrated that alglucosidase alfa leads to stabilization of neuromuscular deficits as well as some degree of functional improvement [23, 24].

ERT with alglucosidase alfa is not a cure for Pompe disease, but it can greatly modify or attenuate the phenotype, improving clinical outcome, quality of life (QOL), and survival.

## Epidemiology

The combined incidence of both forms of Pompe disease varies depending on ethnicity and geographic region, ranging from 1 in 14,000 to 1 in 600,000 reported in African American and Portuguese populations, respectively [25–27].

The worldwide incidence of both forms of the disease is commonly reported to be 1 in 40,000 [1]. The frequency of LOPD is estimated at 1 in 57,000 [28]. However, two prospective trials performed in the context of newborn screening challenge this. The incidence of LOPD in Taiwan based on a prospective newborn screening study is 1/26,466 [2] and the overall incidence of Pompe disease in Austria based on a prospective newborn screening study is 1/8,684 live births [3].

There are no late-onset incidence studies in the MENA region; however the prevalence of IOPD in Emiratis has been reported as 2.66 per 100,000 based on UAE experience from two centers and is likely much higher [29]. Additionally, the high degree of consanguinity in the region results in higher incidence of autosomal recessive diseases in general [30].

## Pathophysiology

Pompe disease is a result of mutations in the *GAA* gene, which is located on the long arm of chromosome 17 (17q25.2-q25.3) [31, 32] and encodes the 105-kDa GAA

enzyme [33]. Mutations in the gene lead to deficiency in the lysosomal enzyme GAA, causing accumulation of lysosomal and non-lysosomal glycogen in multiple tissues [34]. Lysosomal enlargement and rupture, as well as autophagic accumulation, contribute to the progressive myopathy in the disease, with autophagic accumulation causing skeletal muscle destruction in LOPD (Fig. 1).

Due to the broad clinical spectrum of the presenting phenotype, a number of differential diagnoses for Pompe disease should be considered. These differential diagnoses and their features common to Pompe disease are summarized in Table 1.

### Clinical phenotype

LOPD has a wide spectrum of signs and symptoms [1]. While the age of symptom onset has been reported from <12 months of age to 70+ years, the average age at onset of symptoms is between 29 and 33 years, while the mean age at initial diagnosis is 36–43 years [35–38].


LOPD is a multisystem disorder which typically manifests as limb–girdle muscle weakness, respiratory symptoms, and progression to respiratory insufficiency due to diaphragmatic and intercostal muscle weakness. The phenotype can include varying degrees: limb–girdle muscle weakness, scapular winging, neck flexor weakness, abdominal wall musculature involvement, or a lordotic waddling gait [1]. Symptoms may include rigid spine syndrome (RSS), scoliosis, low body mass [38], and

asymptomatic hyperCKemia [39]. Other symptoms may include asymmetrical ptosis, tongue weakness, and dysphagia [35, 38, 40, 41]. Myalgia and fatigue are important symptoms as they are sometimes the presenting complaint [35].

Cardiac symptoms are common in IOPD and while cardiac involvement in LOPD remains somewhat controversial with conflicting reports found in the literature, Wolff–Parkinson–White syndrome has been implicated. A study of 46 consecutive adult patients with LOPD suggests that major cardiac abnormalities are rare [42]. However, another study of the clinical and neurophysiological spectrum of 38 LOPD patients identified three subjects who suffered from arrhythmias due to Wolff–Parkinson–White syndrome despite no echocardiographic signs of cardiomyopathy [1]. Cerebral aneurysms have been reported as complications in LOPD patients, and may be increased in incidence over the general population, however this is not certain [43, 44].

Hearing loss is often described in classic IOPD patients. While it is rarer in LOPD, there have been reports of mild hearing loss due to stapedius muscle or cochlear involvement [45, 46].

Low bone mineral density, scoliosis, and osteoporosis have also been reported in LOPD patients. A study of 46 patients found that bone mineral density was significantly lower in Pompe patients than in healthy individuals, with 26 % of patients classified as having osteoporosis/low bone



**Table 1** Differential diagnosis of LOPD

| Differential condition   | Common symptoms  |
|--|--|
| Limb-girdle muscular dystrophy (LGMD)  | Progressive muscle weakness in the pelvis, legs, and shoulders; elevated CK  |
| Becker muscular dystrophy (BMD)  | Progressive proximal muscle weakness, prominent quadriceps weakness, calf hypertrophy, elevated CK, cardiomyopathy                         |
| Selenoprotein N1-related myopathy  | Spinal rigidity, respiratory failure, muscle hypotrophy  |
| Myasthenia gravis  | Ptosis, ophthalmoplegia, bulbar dysfunction, proximal muscle weakness, fluctuating course  |
| Spinal muscular atrophy  | Progressive proximal muscle weakness and atrophy, respiratory failure, postural tremor, mild elevated CK                                   |
| Polymyositis   | Unexplained muscle weakness with elevated CK   |
| Glycogen storage diseases: IIIa (Debrancher deficiency/Cori), IV (branching enzyme deficiency/Anderson disease), V | Hypotonia, hepatomegaly and hepatic failure, muscle weakness with distal involvement, elevated CK  |
| Danon disease  | Hypertrophic cardiomyopathy, skeletal muscle myopathy  |
| Mitochondrial myopathies   | Hypotonia, hyporeflexia, hepatomegaly. Some forms with hypertrophic cardiomyopathy, muscle weakness, external ophthalmoplegia, elevated CK |
| Lipid storage myopathies   | Fluctuating muscle weakness with respiratory involvement, sometimes bulbar weakness, elevated CK   |

CK creatine kinase. Adapted by permission from Macmillan Publishers Ltd: *Genet Med.* 2006;8(5):267–88 [52] © 2006

mass for chronological age; however this may be a consequence of weakness and reduced mobility, as seen in muscular disorders, and not specific for LOPD [47].

Recent studies have identified LOPD in both symptomatic patients with muscle weakness and patients presenting with presymptomatic hyperCKemia [48–50].

## Diagnosis

With such a wide variation in age of onset and a non-specific symptoms complex, a high degree of clinical suspicion is necessary to diagnose patients with LOPD and a low threshold should be used for clinical screening with dried blood spot (DBS) testing. The diagnosis should be suspected on the clinical presentation and phenotype and the evaluation should then ensue.

## Clinical evaluation

### Creatine kinase

Serum creatine kinase (CK) is elevated in 95 % of patients with LOPD [51], however the range can vary from normal (60–305 IU/L) to 15 times the upper limit of

normal. Concurrent elevation of alanine transaminase (ALT), aspartate transaminase (AST), and lactate dehydrogenase (LDH) from muscle sources are frequently detected [52]. Serum CK may be elevated in presymptomatic LOPD patients [48, 49].

### Forced vital capacity

The forced vital capacity (FVC) should be performed in the upright and supine positions and can be done with a hand-held spirometer. In most normal subjects, FVC in the supine position is 5–10 % less than when upright; a drop of  $\geq 10$  % is suggestive of diaphragmatic weakness and a drop  $>30$  % is associated with severe diaphragmatic weakness [53, 54].

### Electromyography

A conventional electromyograph (EMG) may be normal in patients with LOPD, however studies suggest that approximately 70 % may have a myopathic EMG pattern [1]. Studying the more proximal muscles, including the paraspinal muscles, has been shown to be more likely to reveal abnormalities. In addition to typical myopathic features, myotonic discharges without clinical myotonia have also been described sometimes occurring only in paraspinal muscles [55]. In addition, fibrillation potentials, positive sharp waves, and complex repetitive discharges may be seen [41]. Nerve conduction studies in Pompe disease patients are typically normal [1].

### Dried blood spot testing

When available, DBS testing for GAA activity is the preferred screening test for LOPD as it is a simple, inexpensive, and noninvasive assay [56]. Briefly, a blood spot obtained from the patient is assayed for GAA activity using spectrophotofluorimetry with recombinant GAA used as a calibrator for immuno-quantification [57]. The limitations of the DBS test include logistics, a lack of local facilities to perform the analysis, long turnaround times for testing in some regions of the world, and false-positive results.

A positive DBS is not diagnostic for LOPD and a second test should be performed to confirm the diagnosis. These confirmatory tests can include lymphocytes for GAA analysis, fibroblast cultures again assayed for GAA, gene sequencing, or muscle biopsy with or without GAA enzyme analysis. The diagnostic tests for LOPD are summarized in Table 2.

### Confirmatory tests

**Lymphocytes for GAA** GAA activity cannot be assayed in mixed leukocytes as neutrophils contain maltase gluco-amylase (MGA) which leads to false-negative results [56]. Lymphocytes do not contain MGA and therefore LOPD can be diagnosed by assaying GAA in

**Table 2** Summary of diagnostic tests for LOPD

| Test  | Pompe presentation  |
|---|---|
| Creatine kinase                                 | Varies from normal to 15 times the upper limit of normal  |
| Alanine transaminase and aspartate transaminase | Frequently elevated   |
| Forced vital capacity                           | Reduced in most patients. A drop of $\geq 10\%$ in supine versus upright is suggestive of diaphragmatic weakness and a drop $>30\%$ is associated with severe diaphragmatic weakness  |
| Electromyography                                | Myopathic EMG may be present, particularly in proximal muscles such as the paraspinal muscles. Myotonic discharges without clinical myotonia, fibrillation potentials, positive sharp waves, and complex repetitive discharges may also be seen |
| Dried blood spot                                | GAA activity reduced  |

EMG electromyography, GAA acid alpha-glucosidase

purified lymphocyte preparations. Testing lymphocytes for GAA is minimally invasive and has a rapid turnaround time. If successfully performed, a positive result may preclude the need for a more invasive test such as skin or muscle biopsy. The major limitation is that isolation and purification must be performed within 30 minutes and there is a lack of facilities and appropriately trained staff in most centers. Inclusion of acarbose is recommended to eliminate the interference by MGA when neutrophils are present [56].

**Fibroblast cultures** Enzyme analysis of cultured fibroblasts is the gold standard test for diagnosis. A skin biopsy typically requires local anesthetic and requires 4–6 weeks of cell culture, after which an assay is used to quantify GAA activity. In children and adults with Pompe disease, residual GAA activity is approximately 2–40 % of normal activity [52]. A key advantage is that it may preclude the need for an invasive muscle biopsy; however, the main limitations are the possible failure of fibroblast growth, the long turnaround time (usually 6–8 weeks) and the need for cell culture and enzyme assay facilities.

**Genetic testing** GAA is the only gene in which mutations are known to cause LOPD. Numerous pathogenic variants of the gene have been reported [58]. Mutations are spread across the gene, with particular mutations more common in some populations due to founder effects [52]. Methods for detecting mutations include targeted mutational analysis, full sequence analysis, and deletion/duplication analysis; however none of these have a 100 % mutation detection frequency [25]. The limitations of genetic testing include time, cost, and specificity.

**Muscle biopsy** Muscle biopsy is widely practiced in the assessment of patients with neuromuscular disorders. It can be used as a diagnostic or a confirmatory test in LOPD (Figs. 2 and 3). The procedure is invasive but most adult patients only require local anesthesia. The muscle specimen must be immediately frozen in isopentane, cooled in liquid nitrogen, and shipped on dry ice. Muscle biopsy in LOPD shows the presence of vacuoles that stain positively for glycogen, with accumulation in the lysosomes and cytosol observed in the advanced stages of the disease [52]. The limitations of muscle biopsy include the potential for false-negative results, the scarcity of facilities and personnel to process and interpret the specimens, and the invasive nature of the procedure.

In some cases, muscle biopsy can be normal or show non-specific changes using routine techniques of evaluation. Non-specific changes include lobulated or globular fibers, moth-eaten fibers, degenerative fibers, or even necrotic fibers and ragged-red-fibers or COX-negative fibers [59].


Up to 20–30 % of individuals with LOPD with documented decreased enzyme activity may not show muscle-specific changes and therefore a non-diagnostic muscle biopsy of adult patients does not exclude Pompe disease [60]. Biopsies from patients with LOPD have been read as normal, polymyositis, and others.

#### Whole body/muscle magnetic resonance imaging

Where it is available and feasible, whole body magnetic resonance imaging (MRI) can be used to better define the degree and distribution of muscle involvement and aid in the selection of muscles for biopsy [61]. Furthermore, early recognition of respiratory muscle involvement using MRI could allow an early start of ERT [62]. Although whole body MRI is now being included in clinical trials to monitor patients, its use in clinical practice is not yet recommended for monitoring individual patients.

#### Diagnostic dilemmas

It has previously been reported that diagnosis of Pompe disease is a diagnostic dilemma in itself due to the rarity of the disease and the non-specific phenotype [52]. A number of diagnostic dilemmas are faced in the region. Mutation-related dilemmas include the identification of new variants with an unknown significance for pathology which requires the use of clinical findings and other biochemical parameters for diagnosis. Other diagnostic dilemmas include a positive screening test and only one mutation by genetic testing and positive DBS with unusual clinical features. In these cases the gold standard of fibroblast culture is recommended.




**Fig. 2** Biopsy from right vastus lateralis of a 46-year-old woman with LOPD. She had a long history of muscle weakness presenting with respiratory insufficiency. **a** Prominent fiber size variation and excess internalized nuclei with variable-sized subsarcolemmal and cytoplasmic vacuoles (H&E stain x200). **b** Pronounced vacuolation of many fibers, some vacuoles are slightly red-rimmed (modified Gomori trichrome stain x200). **c** Pronounced glycogen accumulation as intense staining of subsarcolemmal and cytoplasmic vacuoles (PAS stain x200). **d** Immunolabeling of multiple membrane-bound cytoplasmic vacuoles with dystrophin (Dystrophin 1, Biogenex Co. x200). Images provided by Dr Yalda Nilipour

### Consensus recommendations


The experts agreed that the diagnosis of LOPD can be difficult, as the phenotype is heterogeneous and may resemble the clinical features of a number of other neuromuscular disorders; a high clinical suspicion was considered important for the diagnosis of this disease. Fig. 4 displays an algorithm for the diagnosis of LOPD as per

the experts' recommendations. In patients who are symptomatic and have a known case and mutation within the family, investigation should begin with molecular testing.

Muscle weakness, high serum CK values (up to 15-fold) and a decline in pulmonary function were considered by the experts as criteria for suspicion of LOPD. Consensus was achieved among the experts that a DBS screening test



**Fig. 3** Muscle biopsy from left brachioradialis of a 40-year-old man with LOPD. He had had progressive limb-girdle muscle weakness since adulthood. **a** Slight variation in fiber size and some internalized nuclei with tiny cytoplasmic vacuoles in few fibers (H&E x400). **b** Only a little accumulation of glycogen in few fibers as punctate staining (PAS x400). **c** Tiny cytoplasmic vacuoles in few fibers. (Gomori trichrome x400). **d** Immunolabeling of dystrophin. Dot-like labelling of tiny membrane-bound cytoplasmic vacuoles in some fibers (Dystrophin 1, Biogenex Co. x400). Images provided by Dr Yalda Nilipour



should be conducted in patients with unexplained weakness or suspected LOPD in the MENA region.

It was agreed that one of the following confirmatory tests should be conducted after obtaining a positive DBS screening test or when DBS is inconclusive and there is a high degree of clinical suspicion: enzymatic assay on lymphocytes or fibroblasts, genotyping, or muscle biopsy. GAA enzymatic analysis of fibroblasts was selected as the gold standard, although the logistics of this test were considered a limitation (Table 3). The experts agreed and recommend that local facilities need to be developed in each country to perform the required testing.

**Treatment**

**Enzyme replacement therapy**

ERT with alglucosidase alfa has shown disease stabilization or improvement in patients with LOPD. The Late-Onset Treatment Study (LOTS), which investigated the effect of alglucosidase alfa in 90 LOPD patients, identified improved walking distance and stabilization in pulmonary function in the first 78 weeks of treatment, which was maintained at 104 weeks [23].

In a systematic literature review of LOPD therapy, it was reported that in 368 patients from 21 studies, at least two-thirds were stabilized or had improved CK levels and muscular and/or respiratory function following treatment

with alglucosidase alfa [63]. Furthermore, alglucosidase alfa was reported to be well tolerated, with most adverse events categorized as mild to moderate infusion-related reactions. ERT with alglucosidase alfa has been shown to increase life expectancy and survival in IOPD and LOPD [5, 64].

**Table 3** Summary of confirmatory tests for LOPD

| Test                        | Description  | Pompe presentation   |
|-----------------------------|--|--|
| Lymphocytes for GAA         | GAA assayed in purified lymphocyte preparations  | GAA activity reduced   |
| Fibroblast cultures for GAA | GAA assayed in cultured fibroblasts from skin biopsy                                   | GAA activity reduced   |
| Genetic testing             | Targeted mutational analysis, full sequence analysis, or deletion/duplication analysis | Pathogenic mutations may be detected   |
| Muscle biopsy               | Histology or immunohistology of muscle biopsy samples                                  | Vacuoles that stain positively for glycogen, with accumulation in the lysosomes and cytosol observed in the advanced stages of the disease<br><br>GAA activity reduced<br><br>May be normal or show non-specific changes |

GAA acid alpha-glucosidase

A key challenge in the MENA region is access to treatment and availability of alglucosidase alfa.

**Consensus recommendations**

**Initiation**

After a diagnosis of Pompe disease by DBS screening and a confirmatory secondary test such as enzyme testing or genetic studies, treatment with alglucosidase alfa should be initiated depending on the status of the patient (Table 4) [6, 7, 65].

In presymptomatic patients with no signs or symptoms, ERT is not necessary. However these patients should be monitored every 6 months and treatment with alglucosidase alfa initiated if there is evidence of clinical deterioration in muscle or pulmonary function. Presymptomatic patients who have abnormal muscle imaging or muscle biopsy, and patients without clinical signs but with MRI abnormalities in muscles not traditionally tested (e.g. paraspinal muscles), should be considered for treatment with alglucosidase alfa on a case-by-case basis.

ERT with alglucosidase alfa should be initiated in patients with symptoms or signs of Pompe disease, including early signs of muscle weakness or respiratory insufficiency. ERT should be considered irrespective of whether the patient is using noninvasive ventilation. In advanced patients with severe signs or symptoms, alglucosidase alfa should be administered for 1 year and the effectiveness of the treatment monitored. If patients display a stabilization or improvement in symptoms, ERT should continue. Continuation of ERT in other patients should be considered on a case-by-case basis. It should be noted that there are no randomized controlled trials to display efficacy of ERT in advanced patients, however there are some data in the literature showing some benefit in such patients.

**Table 4** Recommendations for initiation of alglucosidase alfa ERT based on patient status

| Patient symptomatology  | Recommendations for alglucosidase alfa ERT   |
|---|--|
| Presymptomatic with no signs or symptoms  | ERT not necessary. Patient should be monitored every 6 months and ERT initiated if there is evidence of clinical deterioration |
| Presymptomatic with abnormal muscle imaging or abnormal muscle biopsy                           | ERT should be considered on a case-by-case basis   |
| Symptomatic with signs or symptoms  | ERT should be initiated in patients with muscle weakness or reduced pulmonary function   |
| Patients with markedly advanced disease, who have lost ambulation and are ventilation-dependent | ERT should be administered for 1 year with evaluation of effectiveness   |

Adapted with permission from Cupler et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45(3):319–33. [6] © 2011 Wiley Periodicals, Inc ERT enzyme replacement therapy

The recommended dosage of alglucosidase alfa is 20 mg/kg body weight administered every 2 weeks as an intravenous infusion [66]. Total infusion volume is determined by patient body weight and should be administered over approximately 4 hrs. Infusion rates should be increased in a step-wise manner, with an initial infusion rate of 1 mg/kg/hr which can be increased by 2 mg/kg/hr every 30 mins until patient tolerance is established, up to a maximum rate of 7 mg/kg/hr.

Anaphylaxis and severe allergic reactions have been observed in patients during, and up to 3 hrs after, alglucosidase alfa infusion. Therefore, it is important that appropriate medical support, including cardiopulmonary resuscitation equipment, is readily available during administration. In the event of anaphylaxis or other severe allergic reactions, immediate discontinuation of administration should be considered and appropriate medical treatment should be initiated. Patients should also be monitored for the development of systemic immune-mediated reactions involving skin and other organs while receiving alglucosidase alfa.

Where it is appropriate and the facilities exist, the goal should be infusions at a local center. Transition of patients to home therapy after 6 months of therapy in an infusion center can be considered based on clinical judgment. This may not be appropriate in patients who have experienced adverse effects due to ERT.

**Monitoring**

Patients with LOPD undergoing ERT with alglucosidase alfa should be clinically monitored every 6 months with the tests described below. Ideally the patients should be assessed by the same examiner at the same time of day (morning or afternoon) to decrease confounding variables. Also the patient should be encouraged to give their best effort. If the patient has experienced a recent intercurrent illness, the assessment should be postponed to allow sufficient recovery to baseline.

**Manual muscle testing** Manual muscle testing (MMT) should be performed to assess skeletal muscle strength using the Medical Research Council (MRC) grading scale (range 0–5) [67]:

- 0 No contraction
- 1 Flicker or trace of contraction
- 2 Active movement, with gravity eliminated
- 3 Active movement against gravity
- 4- Active movement against gravity and resistance to minimal pressure
- 4 Active movement against gravity and resistance to moderate pressure
- 4+ Active movement against gravity and resistance to strong pressure
- 5 Normal power



Muscle groups that should be assessed include: neck muscles, shoulder abduction, elbow flexion and extension, hip flexion and abduction, knee flexion and extension, and foot dorsal and plantar flexion. For consistency, this should be measured by the same examiner, either a physician or a physiotherapist.

**Quantitative muscle testing** Where available, quantitative muscle testing (QMT) should be performed using hand-held dynamometry (HHD) [35, 47]. The strength of muscle groups is measured in Newtons and maximum isometric contraction values are assessed with the break technique, in which the examiner applies adequate force to overcome the examinee, thereby producing an eccentric contraction. HHD values obtained for the different muscle groups are expressed as percentages of age- and sex-matched reference values (e.g. [68]).

**Vital capacity** Around 60 % of LOPD patients have a mild reduction in vital capacity (<80 % predicted) while 30–40 % have a moderate reduction (<60 % predicted) [52]. Screening for diaphragmatic involvement should be performed in the upright and supine positions using a hand-held spirometer. In healthy subjects, vital capacity is 5–10 % less in the supine than the upright position; a drop  $\geq 10$  % is suggestive of diaphragmatic weakness and a drop  $> 30$  % is suggestive of severe diaphragmatic weakness [53]. If diaphragmatic weakness is found, patients should be referred for formal pulmonary function testing (PFT) and possible sleep studies to assess for nocturnal apnea. Full PFTs should be performed where available including maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) as they may be more sensitive to early respiratory muscle weakness [52].

**Six-minute walk test** The 6-min walk test (6MWT) is used for the objective evaluation of functional exercise capacity; the objective is for the patient to walk as far as possible in 6 mins. Detailed methods are available [69], but briefly, the 6MWT should be performed indoors, along a flat, straight, quiet, corridor 30 m in length, with the length of the corridor marked every 3 m and the turnaround points marked with a cone. The starting line, which marks the beginning and end of each 60-m lap, should be marked on the floor. The patient walks the course back and forth and is permitted to slow down, stop and rest as necessary but encouraged to resume walking as soon as they are able. The healthcare practitioner should time the 6 mins, counting the laps to determine the distance covered, and record patient dyspnea and fatigue using the Borg scale pre- and post-test.

**Quality of life measurement** The Short Form 36 (SF36) Health Survey has been widely used as a QOL tool in patients with LOPD [70–72], with LOPD patients shown to have a markedly reduced QOL in the physical health domains and a slightly reduced QOL in the mental health domains when compared with the general population [70]. The SF36 Health Survey has been translated and validated in both Arabic [73] and Farsi [74, 75] languages. Ideally, more disease-specific tools (e.g. the IPA/Erasmus MC Pompe survey [37]) would be used, however those have not been standardized or validated in Arabic or Farsi.

**Laboratory tests** In the first year post-diagnosis, laboratory tests should be performed every 3 months, followed by 6-monthly monitoring in the following years if stable on ERT (Table 5).

**Creatine kinase** ERT therapy has been shown to stabilize or improve CK levels in LOPD patients and their reduction is considered a useful indicator of response to treatment [63]. However, as CK levels can fluctuate, this may be an unreliable indicator unless a consistent and significant reduction is seen.

**GAA antibody titers** A number of factors have been identified as the cause of poor response to ERT, one of which is high, sustained antibody titers (HSAT) [72]. However, while HSAT has been shown to correlate with poor response to ERT in IOPD [76, 77], knowledge of the role of antibodies in the LOPD population is limited. A recent study has shown that HSAT in a subset of LOPD patients is associated with clinical decline; however further studies are required to fully understand impact of antibodies in LOPD [72].

**Audiology assessment** While considered rare, there are reports of mild hearing loss in LOPD patients [45, 46]. It is therefore recommended that an audiology assessment is performed at baseline and then as clinically indicated.

#### Algorithm for treatment of LOPD

In asymptomatic patients with a confirmed diagnosis of Pompe disease, the experts recommended conducting PFTs and muscle strength tests; close monitoring for objective signs and symptoms every 6 months was also recommended (Table 5). Upon onset of signs or symptoms, the experts recommended commencement of ERT with alglucosidase alfa (Fig. 5).

#### Treatment failure

The experts defined treatment failure as objective and persistent deterioration of functions following 52 weeks of therapy. Evaluation should include physical examination, assessment for alternative etiologies of disease

**Table 5** Summary of monitoring assessments to be made during ERT

| Test  | Frequency  |
|---|--|
| Manual muscle testing                               |  |
| Quantitative muscle testing                         |  |
| Vital capacity                                      |  |
| Time on ventilation daily (invasive or noninvasive) | Every 6 months   |
| Six-minute walk test                                |  |
| Quality of life measurement                         |  |
| Creatine kinase                                     | Every 3 months in the first year post-diagnosis            |
| Alanine transaminase                                |  |
| Aspartate transaminase                              | Every 6 months if stable on ERT                            |
| Antibody titers                                     |  |
| Electrocardiography                                 |  |
| Echocardiography                                    | At baseline and repeated regularly if clinically indicated |
| DEXA (bone mineral density)                         |  |
| Audiology assessment                                |  |

DEXA dual-energy X-ray absorptiometry, ERT enzyme replacement therapy

progression (e.g. hypothyroidism, vitamin D deficiency), laboratory studies, muscle MRI, GAA antibody titers, and possible muscle biopsy. In non-responders, treatment should be discontinued and progress monitored if an alternative explanation is not determined. Monitoring should be continued after ERT discontinuation. Restarting ERT should be considered if the rate of deterioration increases after discontinuation of ERT. Individualized therapeutic decisions such as high-dose ERT are at the discretion of the treating physician.

**Management of components of LOPD**

**Respiratory**

**Sleep study**

A sleep study should be performed when there is an abnormal drop of >10 % in FVC between the upright and supine position, or when there are symptoms suggestive of nocturnal hypoventilation or sleep apnea. If the sleep study demonstrates abnormalities then a pulmonologist with interest in neuromuscular disease should assess the patient for possible bi-level positive airway pressure (BPAP) or other noninvasive ventilator support to improve nocturnal respiration.


**Cardiac**

**Electrocardiography**

A study of the clinical spectrum of LOPD patients identified three subjects who suffered from arrhythmias due to Wolff–Parkinson–White syndrome despite no echocardiographic signs of cardiomyopathy [1] and this should therefore be considered during cardiac monitoring of LOPD patients. Some patients may have short PR interval in their electrocardiogram (ECG) secondary to enhanced conduction [42]. Others may have abnormalities reflecting their underlying cardiac disease (e.g. bundle branch block), rather than Pompe disease. As such, ECG should be performed at baseline, and repeated regularly only if clinically indicated.

**Echocardiography**

Unlike patients with the infantile form, patients with LOPD do not typically develop hypertrophy of the left ventricle (LVH) [37, 42, 78]. In a study of 75 adult patients with hypertrophic cardiomyopathy, none had



**Fig. 5** Algorithm for treatment of LOPD. Abbreviations: ERT, enzyme replacement therapy; MRI, magnetic resonance imaging. \*Restarting of ERT with alglucosidase alfa should be considered if there is rapid deterioration post-discontinuation

genetic evidence of Pompe disease [78]. Neither Hagemans et al. nor Soliman et al. found LVH in their series of adult patients with LOPD [37, 42]. Most of the cardiac abnormalities described in patients with LOPD are explained by concurrent underlying diseases, rather than LOPD [42]. ECGs should be performed at baseline, then as clinically indicated.

### **Gastrointestinal issues**

#### ***Gastrointestinal motility dysfunction***

A 2010 study reported gastrointestinal (GI) symptoms of chronic constipation and GI reflux in four out of six LOPD patients studied at a single institution [44]. At 1 year follow-up, the patients reported a marked improvement of intestinal symptoms. Another study reported three LOPD patients with chronic diarrhea, postprandial bloating, and abdominal pain [79]. Two of the patients reported fecal incontinence while the other reported synchronous vomiting and diarrhea; however all GI symptoms were reported to be resolved within the first 6 months of ERT.

#### ***Swallowing dysfunction***

A retrospective review of LOPD patients evaluated at the neuromuscular clinic at Duke University Medical Center identified 12 patients, three of whom had symptoms of oropharyngeal dysphagia [41]. This was categorized as mild in two cases and severe in one, with the degree of swallowing impairment appearing to correlate with overall physical strength and function. Moderate or severe lingual weakness was found to be associated with dysphagia, and swallowing difficulties were generally more oral than pharyngeal in nature. It was concluded that screening for symptoms of dysphagia could help reduce morbidity and mortality, while improving understanding of the LOPD phenotype. A recent study has further demonstrated evidence of lingual weakness in LOPD, with a quantitative assessment showing lingual weakness in 80 % of the sample [80].

### **Diet/Nutrition**

At baseline, a study of 17 patients with LOPD undergoing ERT identified increased fat mass in five patients in severe disease stage despite normal body mass index (BMI) [81]. Fat mass was found to correlate inversely, and lean mass directly, with CK, prealbumin, and albumin levels. ERT resulted in significant increases in BMI and fat mass, and a trend towards increased lean mass. Prealbumin and albumin levels increased as early as after the first months of ERT. This study highlighted that BMI may underestimate fat mass in patients in severe stage of disease, due to altered body composition. Furthermore, patients may have a relative protein malnutrition which is reversed by ERT, this reflecting restoration of normal muscle metabolic pathways. The increased BMI may indicate a reduction in

energy consumption during exercise or respiration, along with clinical improvement.

#### ***High protein diet***

A high-protein diet has been shown to have beneficial effects in Pompe patients [82]. A ventilator-dependent Pompe patient fed a general diet supplemented with branched-chain amino acids, which are the principal amino acids involved in muscle protein synthesis and utilization, showed improved respiratory function and muscle strength, resulting in daytime weaning from the ventilator. The potential advantages of a branched-chain amino acids-supplemented liquid diet over a high-protein diet include theoretical sparing of amino acids required for muscle protein synthesis by providing higher concentrations of postprandial branched-chain amino acids in the circulation, and better tolerance by a ventilator-dependent or debilitated patient.

#### ***Supplements***

Supplementation of LOPD patients with L-alanine reduces protein turnover and catabolism [83]. A study of five subjects found that L-alanine supplementation decreased resting energy expenditure, leucine flux, and leucine oxidation to levels lower than those observed in control subjects. L-alanine has not been studied in combination with ERT.

#### ***Gastrostomy tube***

In patients where muscular weakness affects the ability to eat or where breathing problems interfere with eating, a gastrostomy tube (G-tube) may be necessary for providing adequate nutrition [84]. These may also be used to improve nutrition in some patients who have normal swallowing function.

#### ***Exercise***

An uncontrolled prospective study of 34 patients found that compliance to high-protein and low-carbohydrate nutrition and exercise therapy significantly slowed deterioration of muscle function as measured by the Walton scale, and improved the natural history of disease progression [85]. Another study investigated the effect of exercise training on muscular strength and body composition in five patients with LOPD receiving ERT who underwent a 20-week program of supervised aerobic and progressive resistance exercise training. Exercise training resulted in a significant increase in muscular strength and 6-min walking distance despite no change in total and lower extremity lean body mass, highlighting the benefits of exercise training in patients with LOPD on ERT [86].

Studies have also sought to investigate whether exercise training during ERT infusion increases effectiveness of therapy, however in a study of five LOPD

patients following a 6-month period of exercise training, no significant functional changes in body composition, isometric strength, or 6-min walking distance were identified [87].

### **Bone**

Low bone mineral density and osteoporosis have been reported in LOPD patients [47]. Studies of the effect of ERT on bone mineral density suggest that ERT administration may moderately improve bone mineral density in some, but not all, LOPD patients [88, 89].

### **DEXA scan**

Due to this bone mineral density component of LOPD, it is recommended that patients are screened at baseline with dual-energy X-ray absorptiometry (DEXA) and then as clinically indicated [6, 47, 52].

### **Vitamin D plus calcium +/- bisphosphonates**

Patients with abnormal DEXA z-scores should be supplemented with vitamin D and calcium [47]. There is insufficient evidence to recommend bisphosphonates as a preventative therapy, however their use in LOPD patients should follow the same guidelines as for the general population [6, 52].

### **Others**

#### **Possible increase in cerebral vascular anomalies**

An investigation into cerebrovascular anomalies in six LOPD patients identified brain vascular anomalies, including dolichoectasia of the basilar artery and ectasia of internal carotids, in four out of the six patients [44]. Two patients had clinical signs related to the arteriopathy, including partial paralysis of the third cranial nerve and transient ischemic attacks. ERT at 1 year follow-up was found to have no effect on the size of cerebral vessels and the study concluded that as intracranial artery abnormalities are not infrequent in patients with LOPD, they should be specifically investigated in the presence of unexplained CNS symptoms.

A 2008 case report characterized the thrombotic complications of a basilar artery aneurysm in a young adult with Pompe disease, with the authors concluding that screening of intra-cerebral vessels to potentially diagnose thrombotic and thromboembolic complications may be considered in young adults with Pompe disease [90].

A study published in 2011 reported five LOPD patients with aortic arteriopathy involving primarily the ascending thoracic aorta, highlighting that aneurysmal dilatation of the thoracic aorta is an underreported vascular complication of LOPD [91]. The authors suggested that chest X-ray and echocardiography should be incorporated as initial screening tools for aortic aneurysms in patients with LOPD. Furthermore, contrast-mediated

thoracic CT or MRI may be necessary when ectasia is suspected or the ascending aorta is not visualized.

### **Genetic counseling**

As Pompe is an inherited autosomal recessive disease, it is important to undertake genetic counseling with families that are known to be carriers or when there is diagnosis of a new case in a family. The most common inheritance scenario in Pompe disease is where both parents are asymptomatic carriers; in this instance the risk of Pompe disease is 1 in 4 (25 %), the risk that the child will become a carrier is 2 in 4 (50 %), and the risk that the child will be unaffected is 1 in 4 (25 %). As Pompe disease is an autosomal recessive disorder, typically counseling can be performed with an emphasis on prenatal testing and early diagnosis in the newborn.

### **Pregnancy**

Pregnancies in Pompe disease patients, including cases of spinal anesthesia and Cesarean section, have been shown to result in the birth of healthy infants [92], however the pregnancy should be considered high risk. In 2008 it was reported that a 31-year-old patient with known Pompe disease with symptoms and signs of respiratory dysfunction as well as preeclampsia underwent urgent Cesarean section under regional anesthesia, resulting in the birth of a healthy baby girl.

There are limited data on the use of alglucosidase alfa in pregnant women; however studies in animals have shown reproductive toxicity [93]. While safe continuation of ERT during pregnancy and lactation has been reported in a case study [94], the potential risk for humans is unknown and the decision to use alglucosidase alfa during pregnancy needs to be made on an individual basis [93].

A case study reported a primiparous 40-year-old woman diagnosed with Pompe disease whose clinical condition remained fairly stable until the 25th gestational week, after which problems with mobility and respiration were experienced. Fetal growth, as monitored by ultrasound, was reported to be normal and a healthy boy was born at a gestational age of 37 weeks and 5 days by elective Cesarean section. There were no maternal complications and the child developed normally. The mother's physical condition at 1 year post-partum was similar to prior to her pregnancy. Pharmacokinetic studies following enzyme infusion showed that alglucosidase alfa was secreted into the breast milk, with enzyme activity in the breast milk returning to the pre-infusion level after 24 hrs.

Alglucosidase alfa may be excreted in breast milk and as there are limited data on the effects in neonates exposed to alglucosidase alfa via breast milk, cessation of breastfeeding during use of alglucosidase alfa should be advised [93].

## Future therapies for LOPD

### NeoGAA

NeoGAA has been designed to improve delivery of rhGAA to lysosomes by remodeling the carbohydrate moieties on the enzyme to exhibit a high-affinity ligand for the cation-independent mannose 6-phosphate receptor which is responsible for cellular uptake [95]. *In vivo* studies of administration to Pompe mice demonstrate improved clearance of glycogen from affected muscles when compared with the unmodified rhGAA, suggesting promise in enhancing the efficacy of ERT for Pompe disease [95]. NeoGAA is currently undergoing Phase I clinical trials in humans to assess tolerability, pharmacokinetics, and pharmacodynamics [96].

### GAA fusion protein

BMN 701 is a fusion protein of insulin-like growth factor and GAA which has a high affinity for the cation-independent mannose 6-phosphate receptor [97]. BMN 701 has biochemical properties similar to rhGAA but is delivered more effectively to the lysosomes. *In vivo* studies have shown improved clearance of glycogen in Pompe mouse models and the therapy is now in Phase III trials [97, 98].

### Chaperone therapy

Chaperone therapy, also known as enzyme enhancement therapy (EET), is where pharmacological protein chaperones are co-administered with a protein therapy to improve efficacy. *In vitro* and *in vivo* studies show that co-administration of rhGAA and chaperones such as N-butyldeoxynojirimycin (NB-DNJ) [99] or AT2220 (duvoglustat HCl) [100] results in more efficient correction of enzyme activity, with improved delivery to lysosomes, enhanced enzyme maturation, increased enzyme stability, and greater glycogen reduction. A recently reported Phase II trial showed that co-administration of duvoglustat HCl and rhGAA to Pompe patients increased active plasma rhGAA AUC levels in all Pompe patients and that approximately 70 % of patients had increased muscle rhGAA activity [101].

Chaperone therapy can also be given alone, with the idea that the chaperone will bind to the partially active molecule and traffic it to the lysosome where the acidic pH will dislodge the chaperone and permit the defective enzyme to work [102]. Normally, defective enzymes are tagged for destruction, however the chaperone prevents their degradation. While Phase II trials of chaperone monotherapy have been initiated, they were subsequently discontinued [103] due to safety concerns and the future of chaperone monotherapy remains unclear.

### Gene therapy

Adeno-associated virus (AAV)-mediated delivery of GAA has been shown to result in partial biochemical correction of the skeletal muscles and diaphragm and improved motor function in animal models of Pompe disease [104, 105].

Results from a Phase I/II study of AAV-GAA in a severely affected patient group of five children dependent on mechanical ventilation despite ERT suggest gene therapy may be safe and may lead to modest improvements in volitional ventilatory performance measures [106]. Gene therapy led to significant increases in unassisted tidal volume, as well as an increase in patient tolerance for duration of unassisted breathing. However, further studies in larger, more diverse patient populations are required to understand the efficacy and safety of gene therapy in Pompe disease.

## Discussion

This consensus manuscript is the first to provide region-specific guidelines for the MENA region on the diagnosis and treatment of LOPD. They take into account the challenges that are unique to the region; namely delayed diagnosis, access to diagnostic tools, and access to treatment. Considering that the prevalence of LOPD in the region is at least as high as in other countries, and is likely to be higher, the publication of regional guidelines serves to facilitate the prompt diagnosis, appropriate treatment, and proper monitoring that will improve survival and patient outcomes.

There is a lack of awareness of LOPD in the region, which potentially leads to missed cases, delayed diagnosis, and delayed treatment. There is therefore a need to improve the knowledge of physicians and adult neurologists so that they are aware of LOPD as a potential differential diagnosis in patients presenting with limb-girdle disease.

Another challenge faced within the region is the lack of patient education. The authors are aware that there is a reluctance of patients to seek medical attention in the early stages of the disease, which leads to delayed diagnosis and treatment and poor patient outcomes. This is potentially associated with disease stigma and denial of the disease, which also result in a lack of discussion within families and a missed opportunity for family screening. Another patient challenge in the region is the refusal of lifelong treatment or non-compliance with physician recommendations, especially if the disease is mild in severity. Patients need to be educated to be aware of the disease and the need to seek prompt medical attention.

The authors hope that dissemination of these guidelines will assist healthcare professionals in achieving prompt diagnosis, appropriate treatment, and proper follow-up of LOPD patients in order to reduce the burden of the disease.

## Abbreviations

6MWT: 6-minute walk test; AAV: Adeno-associated virus; ALT: Alanine aminotransferase; AMD: Acid maltase deficiency; AST: Aspartate aminotransferase; BMI: Body mass index; BPAP: Bi-level positive airway pressure; CHO: Chinese hamster ovary; CK: Creatine kinase; DBS: Dried blood spot; DEXA: Dual-energy X-ray absorptiometry; ECG: Electrocardiogram; EET: Enzyme enhancement therapy; EMG: Electromyograph; ERT: Enzyme replacement therapy; FVC: Forced vital capacity; GAA: Acid alpha-glucosidase; GI: Gastrointestinal; GSDII: Glycogen storage disease type II; HHD: Hand-held dynamometry; HSAT: High, sustained antibody titer; IOPD: Infantile-onset Pompe disease; LDH: Lactate dehydrogenase; LOPD: Late-onset Pompe disease; LOTS: Late-Onset Treatment Study; LVH: Left ventricular function; MENA: Middle East and North Africa; MGA: Maltase gluco-amylase; MMT: Manual muscle testing; MRC: Medical Research Council; MRI: Magnetic resonance imaging; PFT: Pulmonary function test; QMT: Quantitative muscle testing; QOL: Quality of life; rhGAA: Recombinant human GAA; RSS: Rigid spine syndrome; SF36: Short Form 36.

## Competing interests

All authors received honoraria and support to travel to the consensus paper working group meeting at which the consensus recommendations presented in this manuscript were discussed. Dr Nouriya Al-Sanna'a, Dr Fawziah Al-Sharif, Dr Saeed Bohlega, Dr Mohamed Hamdan, Dr Nawal Makhseed, Dr Yalda Nilipour, Dr Nuri Shembesh, Dr Rawda Sunbul, Dr Seyed Hassan Tonekaboni, Dr Shahriar Nafissi, Dr Laila Selim and Dr Fatimah Alqarni have nothing to declare. Dr Edward Cupler reports receiving honoraria and consulting fees from Genzyme and Novartis and research support from Merck Serono. Dr Waseem Fathalla reports receiving consultancy fees from Genzyme, Shire and Biomarin. Dr Fatma Al Jasmi reports receiving honoraria for lectures, board membership, consultancy fees and grants from Genzyme, Shire, BioMarine, Orphan Europe and Sobi. Dr Mohammed Al Jumah reports receiving consultancy fees from Genzyme, Merck Serono, Novartis, Biogen and Bayer.

## Authors' contributions

All authors contributed extensively to the work presented in this manuscript. EJC was the chairperson of the Pompe Middle East and North Africa Working Group and led the overall development of the manuscript, in addition to providing expert opinion on treatment strategies for management of Pompe disease. NAS reviewed the pathophysiology. SB addressed the epidemiology and genetic basis of Pompe disease and led the consensus discussion on diagnosis of Pompe disease. WF and FA covered the clinical presentation of infantile-onset and late-onset Pompe disease, respectively. MAH reviewed the cardiac issues related to Pompe disease and ERT. MAJ led the consensus discussion on treatment of late-onset Pompe disease and provided updates on the diagnostic approaches along with RS. YN provided expert opinion on muscle pathology in Pompe disease. SHT led the consensus discussion on treatment of infantile onset Pompe disease and also addressed enzyme replacement therapy in infantile and late-onset Pompe disease. FAJ, NM, FAS, SN, NS, and LS presented their experience in management of Pompe disease in their country and outlined the local challenges to optimal management. All authors read and approved the final manuscript.

## Acknowledgements

Medical writing support in the development of this manuscript was provided by Dr Marcus Corander of Choice Healthcare Solutions, and funded by Genzyme, a Sanofi Company. Genzyme reviewed the manuscript and provided comments for author consideration. The authors would like to thank Dr Dina El-Shafei of Genzyme for her initiation and support of the MENA Working Group that facilitated the process of the guideline manuscript development.

## Author details

<sup>1</sup>Department of Pediatrics, College of Medicine and Health Science, United Arab Emirates University, P.O. Box 17666, Al-Ain, United Arab Emirates. <sup>2</sup>King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, NGH, Riyadh, Kingdom of Saudi Arabia. <sup>3</sup>Prince Mohammed Ben Abdulaziz Hospital, MOH, P.O. Box 22490, Riyadh 11426, Kingdom of Saudi Arabia. <sup>4</sup>Neurology Department, National Neurosciences Institute, King Fahad Medical City, P.O. Box 59046, Riyadh 11525, Kingdom of Saudi Arabia. <sup>5</sup>Johns Hopkins Aramco Healthcare,

Pediatrics Services Division, Building 61/Room D-269, Dhahran, Kingdom of Saudi Arabia. <sup>6</sup>Medical Genetics And Metabolic Consultant, MCH, PO Box 55954, Jeddah 21544, Kingdom of Saudi Arabia. <sup>7</sup>Department of Neurosciences, MBC 76, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Kingdom of Saudi Arabia. <sup>8</sup>Department of Neuroscience, MBC J-76, King Faisal Specialist Hospital and Research Center, P.O. Box 40047, Jeddah 21499, Kingdom of Saudi Arabia. <sup>9</sup>Department of Pediatrics, Division of Child Neurology, Mafraq Hospital, P.O. Box: 2951, Abu Dhabi, United Arab Emirates. <sup>10</sup>KidsHeart: American Fetal & Children's Heart Center, Dubai Healthcare City, P.O. Box 505193, Dubai, United Arab Emirates. <sup>11</sup>Pediatric Department, Jahra Hospital, Ministry of Health, P.O. Box 16586, Qadisiya 35856, Kuwait. <sup>12</sup>Department of Neurology, Tehran University of Medical Sciences, Shariati Hospital, North Kargar Street, Tehran 14114, Iran. <sup>13</sup>Pediatric Pathology Research Center, Mofid Children Hospital, Shahid Beheshti Medical University (SBMU), Shariati Avenue, Tehran 15468-155514, Iran. <sup>14</sup>Pediatric Neurology and Neurometabolic Division, Cairo University Children Hospital (Abo el Reesh), 1-Aly Pasha Ibrahim Street, Near Sayeda Zeinab Metro Station, Cairo, Egypt. <sup>15</sup>Pediatrics and Pediatric Neurology, Benghazi University, P.O. Box 1565, Benghazi, Libya. <sup>16</sup>Department of Pediatrics, Qatif Central Hospital, P.O. Box 18476, Dammam 31911 Eastern Province, Kingdom of Saudi Arabia. <sup>17</sup>Pediatric Neurology Research Center, Mofid Children Hospital, Shahid Beheshti Medical University (SBMU), Shariati Avenue, Tehran 15468-155514, Iran.

Received: 24 March 2015 Accepted: 18 August 2015

Published online: 15 October 2015

## References

- Muller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. *Neuromuscul Disord*. 2007;17:698–706.
- Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL. Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. *J Pediatr*. 2011;158:1023–7. e1021.
- Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. *Lancet*. 2012;379:335–41.
- Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. *Neurology*. 2007;68:99–109.
- Gungor D, Kruijshaar ME, Plug I, D'Agostino Sr RB, Hagemans ML, van Doorn PA, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. *Orphanet J Rare Dis*. 2013;8:49.
- Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, et al. Consensus treatment recommendations for late-onset Pompe disease. *Muscle Nerve*. 2012;45:319–33.
- Llerena Jr JC, Horovitz DM, Marie SK, Porta G, Giugliani R, Rojas MV, et al. The Brazilian consensus on the management of Pompe disease. *J Pediatr*. 2009;155:S47–56.
- Bembi B, Cerini E, Danesino C, Donati MA, Gasperini S, Morandi L, et al. Management and treatment of glycogenosis type II. *Neurology*. 2008;71:S12–36.
- Pompe JC. Over idiopathische hypertrophie van het hart. *Ned Tijdschr Geneesk*. 1932;76:304–12.
- Cori GT. Glycogen structure and enzyme deficiencies in glycogen storage disease. *Harvey Lect*. 1954;48:145–71.
- de Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmans F. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. *Biochem J*. 1955;60:604–17.
- Appelmans F, Wattiaux R, de Duve C. Tissue fractionation studies. 5. The association of acid phosphatase with a special class of cytoplasmic granules in rat liver. *Biochem J*. 1955;59(3):438–45.
- Hers HG. alpha-Glucosidase deficiency in generalized glycogen storage disease (Pompe's disease). *Biochem J*. 1963;86:11–6.
- Baudhuin P, Hers HG, Loeb H. An electron microscopic and biochemical study of type II Glycogenosis. *Lab Invest*. 1964;13:1139–52.
- Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. *N Engl J Med*. 1974;291:989–93.

16. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher's disease. *N Engl J Med*. 1991;324:1464–70.
17. Van der Ploeg AT, Kroos MA, Willemsen R, Brons NH, Reuser AJ. Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. *J Clin Invest*. 1991;87:513–8.
18. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. *Genet Med*. 2001;3:132–8.
19. Van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, Smeitink JA, Van der Ploeg AT. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. *J Inher Metab Dis*. 2001;24:266–74.
20. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. *Pediatrics*. 2004;113:e448–57.
21. Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. *J Pediatr*. 2006;149:89–97.
22. Owens J. 2006 drug approvals: finding the niche. *Nat Rev Drug Discov*. 2007;6:99–101.
23. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. *N Engl J Med*. 2010;362:1396–406.
24. Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. *J Neurol*. 2010;257:91–7.
25. Leslie N, Tinkle BT. Glycogen Storage Disease Type II (Pompe Disease). In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. *Gene reviews*. Seattle (WA): University of Washington, Seattle; 1993.
26. Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. *Eur J Hum Genet*. 2004;12:87–92.
27. Hirschhorn R, Reuser AJ. Glycogen Storage Disease Type II: Acid Alpha-Glucosidase (Acid Maltase) Deficiency. In: Wonsiewicz MNS, Boyle P, editors. *The metabolic and molecular bases of inherited disease*. 8th ed. New York: McGraw-Hill; 2001. p. 3389–420.
28. Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. *Eur J Hum Genet*. 1999;7:713–6.
29. Al-Jasmi FA, Tawfig N, Berniah A, Ali BR, Taleb M, Hertecant JL, et al. Prevalence and novel mutations of lysosomal storage disorders in United Arab Emirates: LSD in UAE. *JIMD Rep*. 2013;10:1–9.
30. Hamamy H. Consanguineous marriages: preconception consultation in primary health care settings. *J Community Genet*. 2012;3:185–92.
31. Honig J, Martiniuk F, D'Eustachio P, Zamfirescu C, Desnick R, Hirschhorn K, et al. Confirmation of the regional localization of the genes for human acid alpha-glucosidase (GAA) and adenosine deaminase (ADA) by somatic cell hybridization. *Ann Hum Genet*. 1984;48:49–56.
32. Kuo WL, Hirschhorn R, Huie ML, Hirschhorn K. Localization and ordering of acid alpha-glucosidase (GAA) and thymidine kinase (TK1) by fluorescence in situ hybridization. *Hum Genet*. 1996;97:404–6.
33. Martiniuk F, Mehler M, Pellicer A, Tzall S, La Badie G, Hobart C, et al. Isolation of a cDNA for human acid alpha-glucosidase and detection of genetic heterogeneity for mRNA in three alpha-glucosidase-deficient patients. *Proc Natl Acad Sci U S A*. 1986;83:9641–4.
34. McCready ME, Carson NL, Chakraborty P, Clarke JT, Callahan JW, Skomorowski MA, et al. Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a Canadian cohort of individuals with glycogen storage disease, type II. *Mol Genet Metab*. 2007;92:325–35.
35. van der Beek NA, de Vries JM, Hagemans ML, Hop WC, Kroos MA, Wokke JH, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. *Orphanet J Rare Dis*. 2012;7:88.
36. Wokke JH, Escolar DM, Pestronk A, Jaffe KM, Carter GT, van den Berg LH, et al. Clinical features of late-onset Pompe disease: a prospective cohort study. *Muscle Nerve*. 2008;38:1236–45.
37. Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. *Brain*. 2005;128:671–7.
38. Schuller A, Wenninger S, Strigl-Pill N, Schofer B. Toward deconstructing the phenotype of late-onset Pompe disease. *Am J Med Genet C: Semin Med Genet*. 2012;160:80–8.
39. Spada M, Porta F, Vercelli L, Pagliardini V, Chiado-Piat L, Boffi P, et al. Screening for later-onset Pompe's disease in patients with paucisymptomatic hyperCKemia. *Mol Genet Metab*. 2013;109:171–3.
40. Dubrovsky A, Corderi J, Lin M, Kishnani PS, Jones HN. Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation. *Muscle Nerve*. 2011;44:897–901.
41. Hobson-Webb LD, Jones HN, Kishnani PS. Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement. *Neuromuscul Disord*. 2013;23:319–23.
42. Soliman OI, van der Beek NA, van Doorn PA, Vletter WB, Nemes A, Van Dalen BM, et al. Cardiac involvement in adults with Pompe disease. *J Intern Med*. 2008;264:333–9.
43. Laforet P, Petiot P, Nicolino M, Orlikowski D, Caillaud C, Pellegrini N, et al. Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease. *Neurology*. 2008;70:2063–6.
44. Sacconi S, Bocquet JD, Chanalet S, Tanant V, Salviati L, Desnuelle C. Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. *J Neurol*. 2010;257:1730–3.
45. Musumeci O, Catalano N, Barca E, Ravaglia S, Fiumara A, Gangemi G, et al. Auditory system involvement in late onset Pompe disease: a study of 20 Italian patients. *Mol Genet Metab*. 2012;107:480–4.
46. Hanisch F, Rahne T, Plontke SK. Prevalence of hearing loss in patients with late-onset Pompe disease: Audiological and otological consequences. *Int J Audiol*. 2013;52:816–23.
47. van den Berg LE, Zandbergen AA, van Capelle CI, de Vries JM, Hop WC, van den Hout JM, et al. Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density. *Bone*. 2010;47:643–9.
48. Montagnese F, Barca E, Musumeci O, Mondello S, Migliorato A, Ciranni A, et al. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. *J Neurol*. 2015;262:968–78.
49. Gutierrez-Rivas E, Bautista J, Vilchez JJ, Muelas N, Diaz-Manera J, Illa I, et al. Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort. *Neuromuscul Disord*. 2015;25:548–53.
50. Preisler N, Lukacs Z, Vinge L, Madsen KL, Husu E, Hansen RS, et al. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. *Mol Genet Metab*. 2013;110:287–9.
51. Ausems MG, Lochman P, van Diggelen OP, Ploos van Amstel HK, Reuser AJ, Wokke JH. A diagnostic protocol for adult-onset glycogen storage disease type II. *Neurology*. 1999;52:851–3.
52. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. *Genet Med*. 2006;8:267–88.
53. American Thoracic Society. ATS/ERS Statement on respiratory muscle testing. *Am J Respir Crit Care Med*. 2002;166:518–624.
54. Prigent H, Orlikowski D, Laforet P, Letilly N, Falaize L, Pellegrini N, et al. Supine volume drop and diaphragmatic function in adults with Pompe disease. *Eur Respir J*. 2012;39:1545–6.
55. Shah DU, Darras BT, Markowitz JA, Jones Jr HR, Kang PB. The spectrum of myotonic and myopathic disorders in a pediatric electromyography laboratory over 12 years. *Pediatr Neurol*. 2012;47:97–100.
56. Winchester B, Bali D, Bodamer OA, Caillaud C, Christensen E, Cooper A, et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. *Mol Genet Metab*. 2008;93:275–81.
57. Umapathysivam K, Hopwood JJ, Meikle PJ. Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. *Clin Chem*. 2001;47:1378–83.
58. Kroos M, Hoogeveen-Westerveld M, Michelakakis H, Pomponio R, Van der Ploeg A, Halley D, et al. Update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants. *Hum Mutat*. 2012;33:1161–5.
59. Baethmann M, Straub V, Reuser A. Pompe disease. *Uni-Med Science: Bremen*; 2008.

60. Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. *J Neurol*. 2005;252:875–84.
61. Carlier RY, Laforet P, Wary C, Mompoin D, Laloui K, Pellegrini N, et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: Involvement patterns. *Neuromuscul Disord*. 2011;21:791–9.
62. Gaeta M, Barca E, Ruggeri P, Minutoli F, Rodolico C, Mazziotti S, et al. Late-onset Pompe disease (LOPD): Correlations between respiratory muscles CT and MRI features and pulmonary function. *Mol Genet Metab*. 2013;110:290–6.
63. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. *J Neurol*. 2013;260:951–9.
64. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. *Genet Med*. 2009;11:210–9.
65. Deegan PB, Cox TM, Waldek S, Lachmann R, Ramaswami U, Jessop E. Guidelines for the Investigation and Management of Late Onset Acid Maltase Deficiency (Type II Glycogen Storage Disease / Pompe Disease). [[http://www.specialisedservices.nhs.uk/library/23/Guidelines\\_for\\_Late\\_Onset\\_Pompe\\_Disease.pdf](http://www.specialisedservices.nhs.uk/library/23/Guidelines_for_Late_Onset_Pompe_Disease.pdf)]
66. Corporation G. Lumizyme prescribing information. Cambridge: MA, USA; 2010.
67. Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45. London, UK: Her Majesty's Stationary Office; 1976.
68. Beenakker EA, van der Hoeven JH, Fock JM, Maurits NM. Reference values of maximum isometric muscle force obtained in 270 children aged 4–16 years by hand-held dynamometry. *Neuromuscul Disord*. 2001;11:441–6.
69. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166:111–7.
70. Hagemans ML, Janssens AC, Winkel LP, Sieradzan KA, Reuser AJ, Van Doorn PA, et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. *Neurology*. 2004;63:1688–92.
71. Gungor D, Schober AK, Kruijshaar ME, Plug I, Karabul N, Deschauer M, et al. Pain in adult patients with Pompe disease: a cross-sectional survey. *Mol Genet Metab*. 2013;109:371–6.
72. Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B, Kishnani PS. The impact of antibodies in late-onset Pompe disease: a case series and literature review. *Mol Genet Metab*. 2012;106:301–9.
73. Sabbah I, Drouby N, Sabbah S, Retel-Rude N, Mercier M. Quality of life in rural and urban populations in Lebanon using SF-36 health survey. *Health Qual Life Outcomes*. 2003;1:30.
74. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. *Qual Life Res*. 2005;14:875–82.
75. Mehraban D, Naderi G, Salehi M. Development of SF-36 questionnaire in the measurement of quality of life in patients on renal replacement therapy in Iran. *Saudi J Kidney Dis Transpl*. 2003;14:15–7.
76. Kishnani PS, Goldenberg PC, DeArmev SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. *Mol Genet Metab*. 2010;99:26–33.
77. Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. *Genet Med*. 2011;13:729–36.
78. Arad M, Maron BJ, Gorham JM, Johnson Jr WH, Saul JP, Perez-Atayde AR, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. *N Engl J Med*. 2005;352:362–72.
79. Bernstein DL, Bialer MG, Mehta L, Desnick RJ. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. *Mol Genet Metab*. 2010;101:130–3.
80. Jones HN, Crisp KD, Asrani P, Sloane R, Kishnani PS. Quantitative assessment of lingual strength in late-onset Pompe disease. *Muscle Nerve*. 2015;51:731–5.
81. Ravaglia S, Danesino C, Moglia A, Costa A, Cena H, Maccarini L, et al. Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis. *Eur J Neurol*. 2010;17:957–62.
82. Mobarhan S, Pintozzi RL, Damle P, Friedman H. Treatment of acid maltase deficiency with a diet high in branched-chain amino acids. *JPEN J Parenter Enteral Nutr*. 1990;14:210–2.
83. Bodamer OA, Halliday D, Leonard JV. The effects of l-alanine supplementation in late-onset glycogen storage disease type II. *Neurology*. 2000;55:710–2.
84. Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT. Disease severity in children and adults with Pompe disease related to age and disease duration. *Neurology*. 2005;64:2139–41.
85. Slonim AE, Bulone L, Goldberg T, Minikes J, Slonim E, Galanko J, et al. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. *Muscle Nerve*. 2007;35:70–7.
86. Terzis G, Dimopoulos F, Papadimas GK, Papadopoulos C, Spengos K, Fatouros I, et al. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. *Mol Genet Metab*. 2011;104:279–83.
87. Terzis G, Krase A, Papadimas G, Papadopoulos C, Kavouras SA, Manta P. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy. *Mol Genet Metab*. 2012;107:669–73.
88. Papadimas G, Terzis G, Papadopoulos C, Areovimata A, Spengos K, Kavouras S, et al. Bone density in patients with late onset Pompe disease. *Int J Endocrinol Metab*. 2012;10:599–603.
89. Papadimas GK, Terzis G, Methenitis S, Spengos K, Papadopoulos C, Vassilopoulou S, et al. Body composition analysis in late-onset Pompe disease. *Mol Genet Metab*. 2011;102:41–3.
90. Refai D, Lev R, Cross DT, Shimony JS, Leonard JR. Thrombotic complications of a basilar artery aneurysm in a young adult with Pompe disease. *Surg Neurol*. 2008;70:518–20.
91. El-Gharbawy AH, Bhat G, Murillo JE, Thurberg BL, Kampmann C, Mengel KE, et al. Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered. *Mol Genet Metab*. 2011;103:362–6.
92. Cilliers HJ, Yeo ST, Salmon NP. Anaesthetic management of an obstetric patient with Pompe disease. *Int J Obstet Anesth*. 2008;17:170–3.
93. EMA. Myozyme: EPAR - Product Information. [[http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/000636/WC500032125.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000636/WC500032125.pdf)]
94. de Vries JM, Brugma JD, Ozkan L, Steegers EA, Reuser AJ, van Doorn PA, et al. First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease. *Mol Genet Metab*. 2011;104:552–5.
95. Zhu Y, Li X, McVie-Wylie A, Jiang C, Thurberg BL, Raben N, et al. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. *Biochem J*. 2005;389:619–28.
96. ClinicalTrials.gov. Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients. [<http://clinicaltrials.gov/show/NCT01898364>]
97. Maga JA, Zhou J, Kambampati R, Peng S, Wang X, Bohnsack RN, et al. Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice. *J Biol Chem*. 2013;288:1428–38.
98. BioMarin. Pompe Clinical Trials. [<https://www.bmrn.com/pipeline/clinical-trials/pompe.php>]
99. Porto C, Cardone M, Fontana F, Rossi B, Tuzzi MR, Tarallo A, et al. The pharmacological chaperone N-butyldeoxyguanosine enhances enzyme replacement therapy in Pompe disease fibroblasts. *Mol Ther*. 2009;17:964–71.
100. Lun Y, Feng J, Xu S, Soska R, Frascella M, Garcia A, et al. Exploring the Use of a Co-formulated Pharmacological Chaperone AT2220 with Recombinant Acid Alpha-Glucosidase for Pompe Disease. In: Proceedings of the LDN World 2013; Orlando, USA. 2013.
101. Kishnani P, Tarnopolsky M, Byrne B, Sivakumar K, Roberts M, Finanger E, et al. Phase 2a Study to Investigate Drug-Drug Interactions between Escalating Doses of AT2220 (Duvoglustat Hydrochloride) and Acid Alfa-Glucosidase in Subjects with Pompe Disease. In: Proceedings of the LDN WORLD 2013; Orlando, USA. 2013.
102. Amicus Therapeutics: Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease. [<http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=313541>]



103. Amicus Therapeutics: Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease. [http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=368188]
104. Byrne BJ, Falk DJ, Pacak CA, Nayak S, Herzog RW, Elder ME, et al. Pompe disease gene therapy. *Hum Mol Genet.* 2011;20:R61–8.
105. Zhang P, Sun B, Osada T, Rodriguez R, Yang XY, Luo X, et al. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. *Hum Gene Ther.* 2012;23:460–72.
106. Smith BK, Collins SW, Conlon TJ, Mah CS, Lawson LA, Martin AD, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. *Hum Gene Ther.* 2013;24:630–40.
107. AANEM. Diagnostic criteria for late-onset (childhood and adult) Pompe disease. *Muscle Nerve.* 2009;40:149–60.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

